ALKSAlkermes plc

ALKS Stock Price, Valuation & Chart | Alkermes plc

Compare

$47.200+0.21 (+0.45%)

At close · 01 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology ALKS intrinsic value ALKS calculated fair value vs price

Overview Financials Dividends Ratios

ALKS Historical price chart

ALKS Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization7.92B

PE Ratio49.68

EPS0.95

Trading Volume1.19M

Today's High/Low47.34/46.65

Dividend Yield0.00

52 Week High/Low55.67/25.17

Shares Outstanding167.76M

ALKS Financial Statement

ALKS Analyst ratings

ALKS Analysis & performance metrics

ALKS Company profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic…

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and…

ALKS Management team

Name

Position

Thomas HarveyCTO

Chief Information Officer & Senior Vice President of IT

Stephen Schiavo

Senior Vice President & Chief Human Resources Officer

Richard F. PopsCEO

Chairman & Chief Executive Officer

Blair C. JacksonCOO

Interim Principal Financial Officer, Executive Vice President, Chief Risk Officer & Chief Operating Officer

David Joseph Gaffin J.D.

Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary

Craig C. Hopkinson M.D.

Executive Vice President of Research & Development and Chief Medical Officer

Samuel J. Parisi

Interim Principal Accounting Officer & Vice President of Finance

C. Todd Nichols

Senior Vice President & Chief Commercial Officer

Name

Position

Thomas HarveyCTO

Chief Information Officer & Senior Vice President of IT

Stephen Schiavo

Senior Vice President & Chief Human Resources Officer

Richard F. PopsCEO

Chairman & Chief Executive Officer

Blair C. JacksonCOO

Interim Principal Financial Officer, Executive Vice President, Chief Risk Officer & Chief Operating Officer

David Joseph Gaffin J.D.

Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary

Craig C. Hopkinson M.D.

Executive Vice President of Research & Development and Chief Medical Officer

Samuel J. Parisi

Interim Principal Accounting Officer & Vice President of Finance

C. Todd Nichols

Senior Vice President & Chief Commercial Officer

Management Team

Thomas HarveyCTO

Chief Information Officer & Senior Vice President of IT

Stephen Schiavo

Senior Vice President & Chief Human Resources Officer

Richard F. PopsCEO

Chairman & Chief Executive Officer

Blair C. JacksonCOO

Interim Principal Financial Officer, Executive Vice President, Chief Risk Officer & Chief Operating Officer

David Joseph Gaffin J.D.

Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary

Craig C. Hopkinson M.D.

Executive Vice President of Research & Development and Chief Medical Officer

Samuel J. Parisi

Interim Principal Accounting Officer & Vice President of Finance

C. Todd Nichols

Senior Vice President & Chief Commercial Officer

Management

Thomas HarveyCTO

Chief Information Officer & Senior Vice President of IT

Stephen Schiavo

Senior Vice President & Chief Human Resources Officer

Richard F. PopsCEO

Chairman & Chief Executive Officer

Blair C. JacksonCOO

Interim Principal Financial Officer, Executive Vice President, Chief Risk Officer & Chief Operating Officer

David Joseph Gaffin J.D.

Executive Vice President, Chief Legal Officer, Chief Compliance Officer & Secretary

Craig C. Hopkinson M.D.

Executive Vice President of Research & Development and Chief Medical Officer

Samuel J. Parisi

Interim Principal Accounting Officer & Vice President of Finance

C. Todd Nichols

Senior Vice President & Chief Commercial Officer

Total 8 executives

ALKS Frequently asked questions

What is Alkermes plc (ALKS) Stock Price?

Current stock price of Alkermes plc (ALKS) stock is $47.200. The stock price is +0.45% higher in the session. The intraday range can be seen from this page. Volume of Alkermes plc (ALKS) stock is 1.19M.

Last updated at 01 Sept 2026, 08:00 pm.

Why is the Alkermes plc (ALKS) stock price going up or down today?

The stock price of Alkermes plc (ALKS) can change with earnings, company news, and overall market sentiment. Alkermes plc operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Alkermes plc stock expensive at its current price?

Whether Alkermes plc looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for ALKS on this page is 49.68. EPS on this page is 0.95. Compare those figures with peers and growth expectations before deciding if the current Alkermes plc price is justified.

How has the stock price of Alkermes plc (ALKS) performed historically?

Historical performance for Alkermes plc (ALKS) is shown on the price chart on this page. Review multi-period moves alongside volume to see how ALKS reacted to past earnings and market events.

Should I buy Alkermes plc (ALKS) stock, at this price?

Buying Alkermes plc (ALKS) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.